{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:52:09Z","timestamp":1788454329562,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    With the increasing importance of nuclear medicine therapy in overall cancer care and the introduction of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 to Japan being imminent, the Policy Recommendations for Promoting Nuclear Medicine Therapy in Japan from the Working Group for Promoting Nuclear Medicine Therapy of the Japan Society of Clinical Oncology (JSCO) aim to identify issues related to nuclear medicine therapy and propose measures to address them, in order to further advance nuclear medicine therapy in Japan. It is necessary to create an environment in which each medical institution can proactively introduce nuclear medicine therapy by taking measures that target discharge criteria, medical fees, and human resource development and link them organically. The Working Group believes that it is necessary to continue examining long-term issues taking into account the changes that have occurred since the introduction of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617, as well as trends in nuclear medicine therapy other than\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 that are expected to be introduced in the future. In addition, as the \u201cAction Plans for Promoting the Production and Use of Medical Radioisotopes\u201d have been formulated and the advancement of nuclear medicine therapy has become one of the nation\u2019s major policy priorities, JSCO will continue to actively work with relevant ministries and local governments to resolve the various issues of nuclear medicine therapy, including the smooth introduction of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617.\n                  <\/jats:p>","DOI":"10.1007\/s10147-025-02858-3","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:55:06Z","timestamp":1759208106000},"page":"2168-2177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-9251","authenticated-orcid":false,"given":"Kotaro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anri","family":"Inaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumasa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Obinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Majima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumu","family":"Yokono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"11","key":"2858_CR1","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/s1470-2045(24)00407-8","volume":"25","author":"M Abdel-Wahab","year":"2024","unstructured":"Abdel-Wahab M, Giammarile F, Carrara M et al (2024) Radiotherapy and theranostics: a lancet oncology commission. Lancet Oncol 25(11):e545\u2013e580. https:\/\/doi.org\/10.1016\/s1470-2045(24)00407-8","journal-title":"Lancet Oncol"},{"issue":"12","key":"2858_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"issue":"3","key":"2858_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.11226\/jaesjsts.35.3_192","volume":"35","author":"S Kinuya","year":"2018","unstructured":"Kinuya S (2018) Current status of radioiodine therapy in the world and perspective in Japan. Offic J Japan Assoc Endocrine Surg Japanese Soc Thyroid Surg 35(3):192\u2013195. https:\/\/doi.org\/10.11226\/jaesjsts.35.3_192","journal-title":"Offic J Japan Assoc Endocrine Surg Japanese Soc Thyroid Surg"},{"issue":"6","key":"2858_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12149-015-0960-z","volume":"29","author":"S Kinuya","year":"2015","unstructured":"Kinuya S, Yoshinaga K, Higuchi T et al (2015) Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors: guideline drafting committee for radiotherapy with (131)I-MIBG, committee for nuclear oncology and immunology, the Japanese society of nuclear medicine. Ann Nucl Med 29(6):543\u2013552. https:\/\/doi.org\/10.1007\/s12149-015-0960-z","journal-title":"Ann Nucl Med"},{"issue":"8","key":"2858_CR5","first-page":"813","volume":"49","author":"S Takano","year":"2022","unstructured":"Takano S, Kobayashi N, Ichikawa Y et al (2022) Indications and Practice of a New Radionuclide Therapy, 177Lu-DOTATATE in Japan. Gan to Kagaku Ryoho Cancer Chemother 49(8):813\u2013820","journal-title":"Gan to Kagaku Ryoho Cancer Chemother"},{"issue":"177","key":"2858_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K et al (2024) 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet (London, England) 404(177):1227\u20131239. https:\/\/doi.org\/10.1016\/s0140-6736(24)01653-2","journal-title":"Lancet (London, England)"},{"issue":"16_suppl","key":"2858_CR7","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa ST, Sartor AO, Saad F et al (2023) PSmaddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 41(16_suppl):TPS5116\u2013TPS5116. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS5116","journal-title":"J Clin Oncol"},{"key":"2858_CR8","unstructured":"Takashi Mizowaki, Makoto Hosono, Hiroji Uemura et al (2025) Evaluation of appropriate treatment infrastructure for radionuclide therapy through discrete event simulation. KAKUIGAKU. In press"},{"issue":"3","key":"2858_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2967\/jnumed.122.265194","volume":"64","author":"P Ravi","year":"2023","unstructured":"Ravi P, Whelpley B, Kelly E et al (2023) Clinical implementation of (177)Lu-PSMA-617 in the United States: lessons learned and ongoing challenges. J Nuclear Med 64(3):349\u2013350. https:\/\/doi.org\/10.2967\/jnumed.122.265194","journal-title":"J Nuclear Med"}],"updated-by":[{"DOI":"10.1007\/s10147-025-02925-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02858-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02858-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02858-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:01:25Z","timestamp":1767891685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02858-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2858"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02858-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-025-02925-9","URL":"https:\/\/doi.org\/10.1007\/s10147-025-02925-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KS, ST, KN, DO, YM, and MN have no conflict of interest. HM received honoraria from Novartis. AI received research funding from Novartis. YK holds an advisory role in Incyte, Takeda Pharmaceutical, Noile-Immune Biotech Inc., Amgen and Abbie; received honoraria from Taiho Pharmaceutical, Lilly, Takeda Pharmaceutical, Kyowa Kirin, and Amgen; and received fees for promotional materials from Taiho Pharmaceutical, Astellas, Lilly, Takeda Pharmaceutical, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Genmab, Incyte, Abbie, Amgen, Merck, Hengrui, Novartis, Ono Pharmaceutical, Noile-Immune Biotech Inc., Kyowa Kirin, and BMS. TM received honoraria and research funding from Novartis. MU received honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, AstraZeneca, MSD, and Nihon Servier. SM received honoraria from Novartis and received scholarship donations from NTT, HUG, Canon Medical Systems, ArkMS, Fujitsu Japan, NTT-DATA, and PSP. TN received honoraria from Astellas, AstraZeneca, Ono Pharmaceutical, Bristol-Myers Squibb, Janssen Pharmaceutical, and MSD. MN serves in a leadership position in PDRadiopharma Inc., and was employed by PeptiDream Inc. MY received honoraria from JSR Corporation. TY received honoraria from Chugai Pharmaceutical, Takeda pharmaceutical, Merck Biopharma, Ono Pharmaceutical, and MSD; received consulting fee from Sumitomo Corporation, and Indivumed; and received research funding from Amgen, Bristol-Myers Squibb, Caris MPI, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus, Miyarisan Pharmaceutical, Molecular Health GmbH, MSD, Natera, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}